PharmaShots Connects Brands & Decision-Makers with Custom Media Solutions PharmaShots Provides Curated News & Insights for the Biopharma & Healthcare Industry PharmaShots is Empowering Decision Makers with Actionable Insights Amplify Your Brand with PharmaShots’ Expert Content Creation & Marketing Solutions PharmaShots Enables Brands to Strategically Connect with Their Target Audiences Deliver Your News to the Right Audience with PharmaShots Newswire CXO TALKS CXO TALKSCXO Talks Podcast | Building Smarter Biotech: Venkat Nelabhotla, CEO of Vyome Holdings, on Driving Innovation Across the US–India Corridor CXO TALKSCXO Talks Podcast | The Road to Acquisition: Oncolytics’ CEO Jared Kelly on Clinical Data, IP & Pharma Partnerships CXO TALKSPharmaShots CXO Talks | Women’s History Month Special: A Conversation with Dr. Emanuela Offidani of Tris Pharma CXO TALKSPharmaShots CXO Talks | A Conversation with Liz Benditt, Founder & CEO, The Balm Box EXCLUSIVE INTERVIEW EXCLUSIVEGona Aziz at HLTH Europe 2026 on the Convergence of AI & 5T MRI: United Imaging’s Strategy for Advancing Precision Healthcare EXCLUSIVEExclusive: A Stimulating Dialogue with Edmund Ben Ami, Co-Founder & CEO of NeuraLight EXCLUSIVEExclusive: Dr. Mónica Domínguez from Smile Train in a Stimulating Conversation with PharmaShots on Why a Healthy Mouth is a Happy Mind EXCLUSIVEExclusive: Kenneth Sake from Blueprint Medicines in an Enlightening Conversation with PharmaShots EXCLUSIVEExclusive Coverage: Dr. Ikshit Sharma from AIMIL Pharmaceuticals in a Stimulating Dialogue Exchange with PharmaShots EXCLUSIVEAdvancing Care for Hematologic Malignancies: Chris Heery from Arcellx in a Stimulating Dialogue Exchange with PharmaShots EXCLUSIVEDecoding Approval: Moitreyee Chatterjee-Kishore from Astellas in an Exclusive Conversation with PharmaShots EXCLUSIVEAdvancing Urothelial Carcinoma Care: Ahsan Arozullah from Astellas Pharma in an Exclusive Interview with PharmaShots LATEST NEWSStay up-to-date Dassault Systèmes to Acquire ArisGlobal for ~$2B 7 hours ago Revolution Medicines Reports the US FDA NDA Acceptance of Daraxonrasib for Previously Treated Metastatic PDAC 8 hours ago Arrowhead Reports P-III (SHASTA-3 & SHASTA-4) Results on Plozasiran in Severe Hypertriglyceridemia (sHTG) 9 hours ago Royalty Pharma Inks ~$425M Deal with Neurimmune to Acquire Royalty Interest in AstraZeneca’s Cliramitug 11 hours ago Repligen to Acquire BioLife for ~$1.5B 12 hours ago GSK Reports the US FDA Approval of Jideytro for Previously Treated ROS1-Positive NSCLC 13 hours ago Read More Your Daily Dose of Biopharma News & Insights Delivered to Your Inbox. Join the PharmaShots Family of 20000+ subscribers Subscribe Now
Revolution Medicines Reports the US FDA NDA Acceptance of Daraxonrasib for Previously Treated Metastatic PDAC 8 hours ago
Arrowhead Reports P-III (SHASTA-3 & SHASTA-4) Results on Plozasiran in Severe Hypertriglyceridemia (sHTG) 9 hours ago
Royalty Pharma Inks ~$425M Deal with Neurimmune to Acquire Royalty Interest in AstraZeneca’s Cliramitug 11 hours ago
